Literature DB >> 29875397

PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies.

Yonghui Sun1, Xingwang Zhao2, Ning Ding3, Hongying Gao1,2, Yue Wu1, Yiqing Yang1, Meng Zhao2, Jinseok Hwang2, Yuqin Song3, Wanli Liu4, Yu Rao5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29875397      PMCID： PMC6028582          DOI： 10.1038/s41422-018-0055-1

Source DB:  PubMed          Journal:  Cell Res        ISSN： 1001-0602            Impact factor:   25.617


× No keyword cloud information.
  12 in total

1.  Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.

Authors:  Lindsay M Morton; Sophia S Wang; Susan S Devesa; Patricia Hartge; Dennis D Weisenburger; Martha S Linet
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

2.  Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase.

Authors:  Zhengying Pan; Heleen Scheerens; Shyr-Jiann Li; Brian E Schultz; Paul A Sprengeler; L Chuck Burrill; Rohan V Mendonca; Michael D Sweeney; Keana C K Scott; Paul G Grothaus; Douglas A Jeffery; Jill M Spoerke; Lee A Honigberg; Peter R Young; Stacie A Dalrymple; James T Palmer
Journal:  ChemMedChem       Date:  2007-01       Impact factor: 3.466

3.  DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation.

Authors:  Georg E Winter; Dennis L Buckley; Joshiawa Paulk; Justin M Roberts; Amanda Souza; Sirano Dhe-Paganon; James E Bradner
Journal:  Science       Date:  2015-05-21       Impact factor: 47.728

4.  Ibrutinib resistance in chronic lymphocytic leukemia.

Authors:  Richard R Furman; Shuhua Cheng; Pin Lu; Menu Setty; Alexendar R Perez; Alijandro R Perez; Ailin Guo; Joelle Racchumi; Guozhou Xu; Hao Wu; Jiao Ma; Susanne M Steggerda; Morton Coleman; Christina Leslie; Y Lynn Wang
Journal:  N Engl J Med       Date:  2014-05-28       Impact factor: 91.245

5.  BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism.

Authors:  Jiaji G Chen; Xia Liu; Manit Munshi; Lian Xu; Nicholas Tsakmaklis; Maria G Demos; Amanda Kofides; Maria Luisa Guerrera; Gloria G Chan; Christopher J Patterson; Kirsten Meid; Joshua Gustine; Toni Dubeau; Patricia Severns; Jorge J Castillo; Zachary R Hunter; Jinhua Wang; Sara J Buhrlage; Nathanael S Gray; Steven P Treon; Guang Yang
Journal:  Blood       Date:  2018-03-01       Impact factor: 22.113

6.  The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.

Authors:  Lee A Honigberg; Ashley M Smith; Mint Sirisawad; Erik Verner; David Loury; Betty Chang; Shyr Li; Zhengying Pan; Douglas H Thamm; Richard A Miller; Joseph J Buggy
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-06       Impact factor: 11.205

7.  Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4.

Authors:  Jing Lu; Yimin Qian; Martha Altieri; Hanqing Dong; Jing Wang; Kanak Raina; John Hines; James D Winkler; Andrew P Crew; Kevin Coleman; Craig M Crews
Journal:  Chem Biol       Date:  2015-06-04

Review 8.  Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain.

Authors:  Abdalla J Mohamed; Liang Yu; Carl-Magnus Bäckesjö; Leonardo Vargas; Rani Faryal; Alar Aints; Birger Christensson; Anna Berglöf; Mauno Vihinen; Beston F Nore; C I Edvard Smith
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

9.  Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.

Authors:  R Eric Davis; Vu N Ngo; Georg Lenz; Pavel Tolar; Ryan M Young; Paul B Romesser; Holger Kohlhammer; Laurence Lamy; Hong Zhao; Yandan Yang; Weihong Xu; Arthur L Shaffer; George Wright; Wenming Xiao; John Powell; Jian-Kang Jiang; Craig J Thomas; Andreas Rosenwald; German Ott; Hans Konrad Muller-Hermelink; Randy D Gascoyne; Joseph M Connors; Nathalie A Johnson; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Wyndham H Wilson; Jan Delabie; Erlend B Smeland; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; J R Cook; Dennis D Weisenburger; Wing C Chan; Susan K Pierce; Louis M Staudt
Journal:  Nature       Date:  2010-01-07       Impact factor: 49.962

10.  Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.

Authors:  John C Byrd; Bonnie Harrington; Susan O'Brien; Jeffrey A Jones; Anna Schuh; Steve Devereux; Jorge Chaves; William G Wierda; Farrukh T Awan; Jennifer R Brown; Peter Hillmen; Deborah M Stephens; Paolo Ghia; Jacqueline C Barrientos; John M Pagel; Jennifer Woyach; Dave Johnson; Jane Huang; Xiaolin Wang; Allard Kaptein; Brian J Lannutti; Todd Covey; Maria Fardis; Jesse McGreivy; Ahmed Hamdy; Wayne Rothbaum; Raquel Izumi; Thomas G Diacovo; Amy J Johnson; Richard R Furman
Journal:  N Engl J Med       Date:  2015-12-07       Impact factor: 91.245
View more
  63 in total

Review 1.  Preclinical and Clinical Advances of Targeted Protein Degradation as a Novel Cancer Therapeutic Strategy: An Oncologist Perspective.

Authors:  Xinrui Yang; He Yin; Richard D Kim; Jason B Fleming; Hao Xie
Journal:  Target Oncol       Date:  2020-12-28       Impact factor: 4.493

2.  A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant BtkC481S mutation in B-cell malignancies.

Authors:  Fu Gui; Jie Jiang; Zhixiang He; Li Li; Yunzhan Li; Zhou Deng; Yue Lu; Xinrui Wu; Guyue Chen; Jingyi Su; Siyang Song; Yue-Ming Zhang; Cai-Hong Yun; Xin Huang; Ellen Weisberg; Jianming Zhang; Xianming Deng
Journal:  Br J Pharmacol       Date:  2019-12-09       Impact factor: 8.739

3.  A MedChem toolbox for cereblon-directed PROTACs.

Authors:  Christian Steinebach; Izidor Sosič; Stefanie Lindner; Aleša Bricelj; Franziska Kohl; Yuen Lam Dora Ng; Marius Monschke; Karl G Wagner; Jan Krönke; Michael Gütschow
Journal:  Medchemcomm       Date:  2019-05-28       Impact factor: 3.597

Review 4.  PROTACs: great opportunities for academia and industry.

Authors:  Xiuyun Sun; Hongying Gao; Yiqing Yang; Ming He; Yue Wu; Yugang Song; Yan Tong; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2019-12-24

Review 5.  PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future.

Authors:  Mariell Pettersson; Craig M Crews
Journal:  Drug Discov Today Technol       Date:  2019-02-13

6.  Bruton tyrosine kinase degradation as a therapeutic strategy for cancer.

Authors:  Dennis Dobrovolsky; Eric S Wang; Sara Morrow; Catharine Leahy; Tyler Faust; Radosław P Nowak; Katherine A Donovan; Guang Yang; Zhengnian Li; Eric S Fischer; Steven P Treon; David M Weinstock; Nathanael S Gray
Journal:  Blood       Date:  2018-12-13       Impact factor: 22.113

7.  Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders.

Authors:  Shang Su; Zimo Yang; Hongying Gao; Haiyan Yang; Songbiao Zhu; Zixuan An; Juanjuan Wang; Qing Li; Sarat Chandarlapaty; Haiteng Deng; Wei Wu; Yu Rao
Journal:  J Med Chem       Date:  2019-08-02       Impact factor: 7.446

Review 8.  Critical Assessment of Targeted Protein Degradation as a Research Tool and Pharmacological Modality.

Authors:  Milka Kostic; Lyn H Jones
Journal:  Trends Pharmacol Sci       Date:  2020-03-26       Impact factor: 14.819

9.  Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta.

Authors:  Nan Bai; Sven A Miller; Grigorii V Andrianov; Max Yates; Palani Kirubakaran; John Karanicolas
Journal:  J Chem Inf Model       Date:  2021-02-24       Impact factor: 4.956

10.  Snapshots and ensembles of BTK and cIAP1 protein degrader ternary complexes.

Authors:  James Schiemer; Reto Horst; Yilin Meng; Justin I Montgomery; Yingrong Xu; Xidong Feng; Kris Borzilleri; Daniel P Uccello; Carolyn Leverett; Stephen Brown; Ye Che; Matthew F Brown; Matthew M Hayward; Adam M Gilbert; Mark C Noe; Matthew F Calabrese
Journal:  Nat Chem Biol       Date:  2020-11-16       Impact factor: 15.040
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.